Related Experiment Videos
Biomarkers for Pediatric Acute Respiratory Distress Syndrome: A Systematic Review
Fuxiang Yang1, Jiahuan Zou2, Ling Zheng3
1Department of Neonatology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi City, Guizhou Province, 563000, People's Republic of China.
Insights
Nine biomarkers show potential for diagnosing pediatric acute respiratory distress syndrome (PARDS) in critically ill children. Further research is needed to validate these biomarkers for consistent clinical use.
Area of Science:
- Critical Care Medicine
- Pediatric Pulmonology
- Biomarker Discovery
Background:
- Pediatric acute respiratory distress syndrome (PARDS) is a severe condition in critically ill children with significant short- and long-term consequences.
- Current diagnostic criteria (Berlin definition) present challenges in pediatric populations, hindering early detection and clinical application.
- Existing evidence on biomarkers for PARDS diagnosis, prediction, and prognosis is fragmented, necessitating a systematic review.
Purpose of the Study:
- To systematically synthesize evidence on biomarkers for the diagnosis, prediction, and prognosis of PARDS in critically ill children.
- To identify and categorize potential biomarkers based on their underlying mechanisms.
- To evaluate the diagnostic and predictive capabilities of identified biomarkers.
Main Methods:
- A comprehensive systematic literature search was conducted across multiple databases up to September 12, 2025.
- Study quality was assessed using the Revised Newcastle-Ottawa Scale and QUADAS-2.
- Data extraction focused on study characteristics, biomarker details, PARDS criteria, and outcome measures.
Main Results:
- Nine studies involving 759 children met the inclusion criteria, identifying nine biomarkers across epithelial, stress response, inflammatory, and endothelial injury pathways.
- Six biomarkers exhibited strong predictive and diagnostic capabilities (AUC > 0.80), while three showed moderate efficacy (AUC 0.60-0.80).
- Identified biomarkers include CC16, Glypican-4, nucleosomes, Gal-3BP, miR-424, mirR-21, HBP, PGRN, and VWF.
Conclusions:
- The nine identified biomarkers show promise for PARDS assessment in pediatric critical care.
- Inconsistent clinical utility highlights the need for further validation.
- Future large-scale, multicenter prospective studies and technological advancements are crucial for optimizing biomarker use in PARDS management.
Objective:
Pediatric acute respiratory distress syndrome (PARDS) is a common and severe complication in critically ill children, significantly impacting both short-term and long-term outcomes. Diagnosis currently relies on the Berlin definition; however, the applicability of existing diagnostic criteria across different clinical settings remains challenging, particularly in pediatric populations, hindering early recognition and clinical implementation. Biomarkers have demonstrated potential in PARDS diagnosis, prediction, and prognosis assessment, but a systematic synthesis of existing evidence remains lacking.
Methods:
We systematically searched PubMed, Cochrane Library, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang Database, VIP Database, SinoMed, and Scopus from their inception to September 12, 2025. Study quality was assessed using the Revised Newcastle-Ottawa Scale and the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2). Data extraction included study characteristics, biomarker names, research objectives, sample types, sampling time points, biomarker types, PARDS diagnostic criteria, and outcome measures.
Results:
A total of 4889 publications were screened, with 9 studies of moderate to high quality (score >6) ultimately included, involving 759 critically ill children (median age range: 1.8-14.7 years; 641 [63.8%] male). Nine biomarkers were identified and categorized into four mechanisms: epithelial injury (CC16), stress response (Glypican-4, nucleosomes), inflammatory response (Gal-3BP, miR-424, mirR-21, HBP, PGRN), and endothelial injury (VWF). Six biomarkers demonstrated strong predictive and diagnostic capabilities (AUC > 0.80), while the remaining three showed moderate efficacy (AUC 0.60-0.80).
Conclusion:
Although the nine biomarkers demonstrate potential in PARDS assessment, their clinical utility remains inconsistent. Future large-scale, multicenter prospective validation studies are needed. Combining advanced technologies to optimize existing biomarkers and explore new candidates will enhance the prediction, diagnosis, and management of PARDS.
Related Concept Videos
Acute Respiratory Failure-IV
Assessment of Respiration
Subjective Assessment: Nurses interview the patient to gather information directly during the subjective assessment. It includes questions about the individual's medical history, medications, and symptoms, focusing on past respiratory conditions like asthma or COPD,...
Respiratory Assessment: Purpose and Indications
Objectives and Importance:
The primary goal of respiratory assessment is to evaluate patients at early risk of clinical deterioration. Since respiratory distress often precedes other signs of declining health, breathing patterns and sounds become a...
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Assessment of Airway, Skin Color, and Use of Accessory Muscles
Introduction
The initial evaluation of a patient's respiratory system...
Assessment of Ventilation I: Respiratory Rate
A Ventilation assessment is critical for monitoring a patient's health status. Respiration, one of the most accessible vital signs, provides insights into the function of numerous body systems and can indicate serious health issues, such as brainstem injuries from head trauma.
Critical Guidelines for Assessing Ventilation: